Respiratory Therapy Area Unit, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Eur J Pharmacol. 2013 Mar 15;704(1-3):49-57. doi: 10.1016/j.ejphar.2013.02.022. Epub 2013 Feb 27.
Loss of function mutations in the two key proteins which constitute Calcium-Release Activated Calcium (CRAC) channels demonstrate the critical role of this ion channel in immune cell function. The aim of this study was to demonstrate that inhibition of immune cell activation could be achieved with highly selective inhibitors of CRAC channels in vitro using cell preparations from human, rat, mouse and guinea-pig. Two selective small molecule blockers of CRAC channels; GSK-5498A and GSK-7975A were tested to demonstrate their ability to inhibit mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a variety of species. Both GSK-5498A and GSK-7975A completely inhibited calcium influx through CRAC channels. This led to inhibition of the release of mast cell mediators and T-cell cytokines from multiple human and rat preparations. Mast cells from guinea-pig and mouse preparations were not inhibited by GSK-5498A or GSK-7975A; however cytokine release was fully blocked from T-cells in a mouse preparation. GSK-5498A and GSK-7975A confirm the critical role of CRAC channels in human mast cell and T-cell function, and that inhibition can be achieved in vitro. The rat displays a similar pharmacology to human, promoting this species for future in vivo research with this series of molecules. Together these observations provide a critical forward step in the identification of CRAC blockers suitable for clinical development in the treatment of inflammatory disorders.
丧失功能的突变在两个关键蛋白中,这两个蛋白构成钙释放激活钙(CRAC)通道,证明了这种离子通道在免疫细胞功能中的关键作用。本研究的目的是证明,使用来自人、大鼠、小鼠和豚鼠的细胞制剂,在体外使用 CRAC 通道的高选择性抑制剂,能够抑制免疫细胞的激活。两种选择性的小分子 CRAC 通道抑制剂;GSK-5498A 和 GSK-7975A 被测试,以证明它们能够抑制肥大细胞介质的释放,并抑制多种物种的 T 细胞前炎性细胞因子的释放。GSK-5498A 和 GSK-7975A 均可完全抑制 CRAC 通道的钙离子内流。这导致了肥大细胞介质和 T 细胞因子从多种人源和大鼠制剂中的释放受到抑制。来自豚鼠和小鼠制剂的肥大细胞不受 GSK-5498A 或 GSK-7975A 的抑制;然而,来自小鼠制剂的 T 细胞的细胞因子释放被完全阻断。GSK-5498A 和 GSK-7975A 证实了 CRAC 通道在人类肥大细胞和 T 细胞功能中的关键作用,并且可以在体外实现抑制。大鼠显示出与人相似的药理学,促进了该物种在未来使用这一系列分子进行体内研究。这些观察结果为鉴定适合于炎症性疾病治疗的 CRAC 抑制剂的临床开发提供了一个关键的前进步骤。